OncRef

Clinical Trial: NCT02823990

TG4010 and Nivolumab in Patients With Lung Cancer

Status:

COMPLETED

Phase:

Phase 2

Lead Sponsor:Megan Daly, MD
Information Provided By:University of California, Davis
Last Update Posted:2025-11-10

Study Overview

Brief Summary

This phase II trial studies how well TG4010 and nivolumab work in previously treated patients with non-small cell lung cancer. Vaccines that are made from a gene-modified virus, such as TG4010, may help the body build an effective immune response to kill tumor cells. Monoclonal antibodies, such as nivolumab, interfere with the ability of tumor cells to grow and spread. Giving TG4010 and nivolumab together may work better in previously treated patients with non-small cell lung cancer.

Official Title

Phase II Trial of TG4010 Plus Nivolumab in Previously Treated Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC)

Conditions

Recurrent Non-Small Cell Lung Carcinoma, Stage I Non-Small Cell Lung Cancer, Stage II Non-Small Cell Lung Cancer, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer

Intervention / Treatment

  • Biological: TG4010
  • Biological: Nivolumab

Other Study ID Numbers

  • 885316
  • UCDCC#263
  • UCDCC#263
  • P30CA093373
  • NCI-2016-00960

Start Date (Actual)

2016-12-14

Primary Completion Date (Actual)

2021-02-24

Study Completion Date (Actual)

2021-02-24

Enrollment (Actual)

13

Study Type

Interventional

Phase

Phase 2